Organon & Co.OGN

時価総額

$18.7億

PER

女性向け医薬品・バイオシミラ製品を手掛ける大手。避妊薬や不妊治療薬、70超の医薬品ポートフォリオを展開。2024年10月にDermavantを買収（買収対価581百万ドル、追加マイルストーン最大10億2500万ドル）。欧州、米国、アジアに6製造拠点を有するグローバル展開。

	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	1,351	917	1,023	864
Depreciation	92	96	120	132
Amortization	103	116	116	145
Impairment of assets	7	9	-	-
Acquired in-process research and development and milestones	-	-	8	81
Contingent consideration	-	-	-	11
Deferred income tax benefit	-288	-18	-485	-160
Stock-based compensation	59	75	101	105
Unrealized foreign exchange (gain) loss	-	18	-40	2
Other	-12	-26	-31	-41
Accounts receivable	277	123	212	-383
Inventories	138	220	230	131
Other current assets	-353	43	10	236
Trade accounts payable	663	-237	163	-157
Accrued and other current liabilities	329	172	102	-101
Income taxes payable	-119	7	16	-65
Other	-55	8	-16	-29
Net Cash Flows Provided by Operating Activities	-	-	-	939
Capital expenditures	192	196	251	175
Proceeds from sale of property, plant and equipment	7	7	1	4
Acquired in-process research and development and milestones	104	107	8	71
Dermavant acquisition, net of cash acquired	-	-	-	166
Purchase of product rights and asset acquisition	192	124	2	105
Net Cash Flows Used in Investing Activities	-	-	-	-513
Proceeds from debt	9,470	-	80	1,186
Repayments of debt	112	108	338	1,197
Payment of long-term debt issuance costs	118	-	-	38
Net transfers to Merck & Co., Inc.	-440	24	-	-
Employee withholding taxes related to stock-based awards	-	11	17	22
Dividend payments	145	290	294	297
Net Cash Flows Used in Financing Activities	-	-	-	-368
Effect of Exchange Rate Changes on Cash and Cash Equivalents	23	-36	17	-76
Net Decrease in Cash and Cash Equivalents	667	-31	-13	-18